Prognostic significance of CREB-binding protein and CD81 expression in primary high grade non-muscle invasive bladder cancer: Identification of novel biomarkers for bladder cancer using antibody microarray

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Lee, Myung Shin ^a   Kim, Joo Heon ^a   Lee, Ji Su ^a   Yun, Seok Joong ^b   Kim, Wun Jae ^b   Ahn, Hanjong ^c   Park, Jinsung ^a  

^a Eulji University School of Medicine   (South Korea)

^b Chungbuk National University College of Medicine   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD81 ANTIGEN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CD81 PROTEIN, HUMAN;

ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; NON MUSCLE INVASIVE BLADDER CANCER; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SEX DIFFERENCE; WESTERN BLOTTING; CELL CULTURE; DISEASE COURSE; KAPLAN MEIER METHOD; METABOLISM; PATHOLOGY; PROCEDURES; PROGNOSIS; TUMOR INVASION; URINARY BLADDER NEOPLASMS; VALIDATION STUDY;

ANTIGENS, CD81; BIOMARKERS; CELLS, CULTURED; CREB-BINDING PROTEIN; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MICROARRAY ANALYSIS; NEOPLASM INVASIVENESS; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 84928532109     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125405     Document Type: Article

References (35)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. doi: 10.3322/caac.20107 PubMed PMID: 21296855.
2. Spruck CH 3rd, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer research. 1994; 54(3):784-8. PubMed PMID: 8306342.
3. van Rhijn BW, Vis AN, van der Kwast TH, Kirkels WJ, Radvanyi F, Ooms EC, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol. 2003; 21(10):1912-21. PubMed PMID: 12743143.
4. Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, Matos T, Cordon-Cardo C. Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol. 2010; 28(4):401-8. Epub 2010/07/09. doi: 10.1016/j.urolonc.2009.04.019 PubMed PMID: 20610278.
5. Sylvester RJ, van der Meijden AP, OosterlinckW, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49(3):466-5; discussion 75-7. Epub 2006/01/31. doi: 10.1016/j.eururo.2005.12.031 PubMed PMID: 16442208.
6. Thomas F, Rosario DJ, Rubin N, Goepel JR, Abbod MF, Catto JW. The long-term outcome of treated high-risk nonmuscle-invasive bladder cancer: time to change treatment paradigm? Cancer. 2012; 118 (22):5525-34. Epub 2012/05/01. doi: 10.1002/cncr.27587 PubMed PMID: 22544645.
7. Hoque MO, Lee CC, Cairns P, Schoenberg M, Sidransky D. Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer research. 2003; 63(9):2216-22. Epub 2003/05/03. PubMed PMID: 12727842.
8. Simon R, Struckmann K, Schraml P, Wagner U, Forster T, Moch H, et al. Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene. 2002; 21(16):2476-83. Epub 2002/04/24. doi: 10.1038/sj.onc.1205304 PubMed PMID: 11971182.
9. Park J, Song C, Shin E, Hong JH, Kim CS, Ahn H. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy? Urol Oncol. 2013; 31(6):849-56. Epub 2011/07/26. doi: 10.1016/j.urolonc.2011.06.004 PubMed PMID: 21782482.
10. Shariat SF, Karam JA, Lerner SP. Molecular markers in bladder cancer. Curr Opin Urol. 2008; 18(1):1-8. Epub 2007/12/20. doi: 10.1097/MOU.0b013e3282f1c5c1 PubMed PMID: 18090481.
11. Kopf E, Zharhary D. Antibody arrays-an emerging tool in cancer proteomics. Int J Biochem Cell Biol. 2007; 39(7-8):1305-17. Epub 2007/06/30. S1357-2725(07)00142-2 [pii]doi: 10.1016/j.biocel.2007.04.029 PubMed PMID: 17600752.
12. Sanchez-Carbayo M, Socci ND, Lozano JJ, Haab BB, Cordon-Cardo C. Profiling bladder cancer using targeted antibody arrays. Am J Pathol. 2006; 168(1):93-103. Epub 2006/01/10. doi: 10.2353/ajpath.2006.050601 PubMed PMID: 16400012; PubMed Central PMCID: PMC1592677.
13. Srinivasan H, Allory Y, Sill M, Vordos D, Alhamdani MS, Radvanyi F, et al. Prediction of recurrence of non muscle-invasive bladder cancer by means of a protein signature identified by antibody microarray analyses. Proteomics. 2014; 14(11):1333-42. Epub 2014/03/13. doi: 10.1002/pmic.201300320 PubMed PMID: 24610664.
14. Linden M, Segersten U, Runeson M, Wester K, Busch C, Pettersson U, et al. Tumour expression of bladder cancer-associated urinary proteins. BJU Int. 2013; 112(3):407-15. Epub 2013/03/09. doi: 10.1111/j.1464-410X.2012.11653.x PubMed PMID: 23470167.
15. Sobin LH, Gospodarowicz MK, Wittekind C, International Union against Cancer. TNM classification of malignant tumours. 7th ed. Chichester, West Sussex, UK; Hoboken, NJ: Wiley-Blackwell; 2010. xx, 310 p. p.
16. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005; 97(16):1180-4. doi: 10.1093/jnci/dji237 PubMed PMID: 16106022.
17. Park J, Song C, Hong JH, Park BH, Cho YM, Kim CS, et al. Prognostic significance of non-papillary tumor morphology as a predictor of cancer progression and survival in patients with primary T1G3 bladder cancer. World J Urol. 2009; 27(2):277-83. Epub 2008/11/21. doi: 10.1007/s00345-008-0350-4 PubMed PMID: 19020879.
18. Jones TD, Wang M, Eble JN, MacLennan GT, Lopez-Beltran A, Zhang S, et al. Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res. 2005; 11(18):6512-9. doi: 10.1158/1078-0432.CCR-05-0891 PubMed PMID: 16166427.
19. Moon KM, Park YH, Lee JS, Chae YB, Kim MM, Kim DS, et al. The effect of secretory factors of adipose-derived stem cells on human keratinocytes. Int J Mol Sci. 2012; 13(1):1239-57. doi: 10.3390/ijms13011239 PubMed PMID: 22312315; PubMed Central PMCID: PMC3269749.
20. Lee MS, Jones T, Song DY, Jang JH, Jung JU, Gao SJ. Exploitation of the Complement System by Oncogenic Kaposi's Sarcoma-Associated Herpesvirus for Cell Survival and Persistent Infection. PLoS Pathog. 2014; 10(9):e1004412. Epub 2014/09/26. doi: 10.1371/journal.ppat.1004412 PubMed PMID: 25254972; PubMed Central PMCID: PMC4177982.
21. Kim JH, Park J. Prognostic significance of heme oxygenase-1, S100 calcium-binding protein A4, and syndecan-1 expression in primary non-muscle-invasive bladder cancer. Hum Pathol. 2014. doi: 10.1016/j.humpath.2014.04.020 PubMed PMID: 24957789.
22. Kim JH, Bogner PN, Baek SH, Ramnath N, Liang P, Kim HR, et al. Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic target. Clin Cancer Res. 2008; 14(8):2326-33. Epub 2008/04/17. doi: 10.1158/1078-0432.CCR-07-4457 PubMed PMID: 18413821.
23. Iyer NG, Ozdag H, Caldas C. p300/CBP and cancer. Oncogene. 2004; 23(24):4225-31. doi: 10.1038/sj.onc.1207118 PubMed PMID: 15156177.
24. Song Y, Li L, Ou Y, Gao Z, Li E, Li X, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014; 509(7498):91-5. doi: 10.1038/nature13176 PubMed PMID: 24670651.
25. Gao Y, Geng J, Hong X, Qi J, Teng Y, Yang Y, et al. Expression of p300 and CBP is associated with poor prognosis in small cell lung cancer. International journal of clinical and experimental pathology. 2014; 7(2):760-7. PubMed PMID: 24551300; PubMed Central PMCID: PMC3925924.
26. Boorjian SA, Heemers HV, Frank I, Farmer SA, Schmidt LJ, Sebo TJ, et al. Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Endocr Relat Cancer. 2009; 16(1):123-37. Epub 2008/10/11. doi: 10.1677/ERC-08-0124 PubMed PMID: 18845648; PubMed Central PMCID: PMC2674368.
27. Yoo TH, Ryu BK, Lee MG, Chi SG. CD81 is a candidate tumor suppressor gene in human gastric cancer. Cell Oncol (Dordr). 2013; 36(2):141-53. Epub 2012/12/25. doi: 10.1007/s13402-012-0119-z PubMed PMID: 23264205.
28. Mazzocca A, Liotta F, Carloni V. Tetraspanin CD81-regulated cell motility plays a critical role in intrahepatic metastasis of hepatocellular carcinoma. Gastroenterology. 2008; 135(1):244-56 e1. Epub 2008/05/10. doi: 10.1053/j.gastro.2008.03.024 PubMed PMID: 18466772.
29. Tejera E, Rocha-Perugini V, Lopez-Martin S, Perez-Hernandez D, Bachir AI, Horwitz AR, et al. CD81 regulates cell migration through its association with Rac GTPase. Molecular biology of the cell. 2013; 24(3):261-73. doi: 10.1091/mbc.E12-09-0642 PubMed PMID: 23264468; PubMed Central PMCID: PMC3564539.
30. White A, Lamb PW, Barrett JC. Frequent downregulation of the KAI1(CD82) metastasis suppressor protein in human cancer cell lines. Oncogene. 1998; 16(24):3143-9. doi: 10.1038/sj.onc.1201852 PubMed PMID: 9671393.
31. Feng J, He W, Song Y, Wang Y, Simpson RJ, Zhang X, et al. Platelet-derived growth factor receptor beta: a novel urinary biomarker for recurrence of non-muscle-invasive bladder cancer. PloS one. 2014; 9(5):e96671. doi: 10.1371/journal.pone.0096671 PubMed PMID: 24801713; PubMed Central PMCID: PMC4011858.
32. Imao T, Koshida K, Endo Y, Uchibayashi T, Sasaki T, Namiki M. Dominant role of E-cadherin in the progression of bladder cancer. J Urol. 1999; 161(2):692-8. Epub 1999/01/23. PubMed PMID: 9915485.
33. Gabriel U, Bolenz C, Michel MS. Experimental models for therapeutic studies of transitional cell carcinoma. Anticancer research. 2007; 27(5A):3163-71. PubMed PMID: 17970057.
34. Eckner R, Arany Z, Ewen M, Sellers W, Livingston DM. The adenovirus E1A-associated 300-kD protein exhibits properties of a transcriptional coactivator and belongs to an evolutionarily conserved family. Cold Spring Harbor symposia on quantitative biology. 1994; 59:85-95. PubMed PMID: 7587135.
35. Arany Z, Sellers WR, Livingston DM, Eckner R. E1A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators. Cell. 1994; 77(6):799-800. PubMed PMID: 8004670.